ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tamsulosin

Also written as “tamsulosin hydrochloride”, “Tamsulosin (0.4 mg/j)” and “tamsulosin”.

Its studies are mostly in Prostatic Hyperplasia · Lower Urinary Tract Symptoms · Erectile Dysfunction · Urologic Diseases · Urinary Bladder, Neurogenic, led by 15 companies.

Drug pageTamsulosin: every studyMany companies study it; this page follows only the 56 they lead. All 155 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 18, 201456 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only140 open or runningphase 4since Sep 18, 2014Jun 19, 2006none ahead
Astellas Pharmaits history only100 open or runningphase 4since Mar 17, 2016Jul 25, 2007none ahead
GlaxoSmithKline90 open or runningphase 4since Feb 10, 2011Aug 24, 2004none ahead
Hanmi Pharmaceuticalits history only50 open or runningphase 3since Feb 23, 2015Sep 4, 2014none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Sep 2, 2015Sep 15, 2014none ahead
Menarini Groupits history only33 open or runningphase 1since Jul 22, 2025Jul 22, 2025none ahead
GL Pharm Techits history only20 open or runningphase 3since Nov 11, 2014Feb 24, 2014none ahead
Jeil Pharmaceuticalits history only20 open or runningphase 3since Nov 21, 2016Jul 1, 2014none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Jun 22, 2010Jun 22, 2010none ahead
adiumits history only10 open or runningno phasesince Jul 7, 2026Jul 7, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2004First study: phase 3 study in Prostatic HyperplasiaFirst studyNCT00090103 · 4,844 enrolled · United States, Argentina, Belgium and more
  2. Feb 10, 2011Phase 4 study in Prostatic HyperplasiaNCT01294592 · 742 enrolled · France, Germany, Greece and more
  3. Jun 28, 2012Phase 4 study in Prostatic HyperplasiaNCT01673490 · 59 enrolled · Vietnam
  4. Aug 2, 2012Phase 1 study in Prostatic HyperplasiaNCT01657851 · 35 enrolled · Russian Federation
  5. Jan 24, 2013Phase 4 study in Prostatic HyperplasiaNCT01777269 · 489 enrolled · Australia, France, Germany and more
  6. Oct 4, 2013Phase 1 study in Prostatic HyperplasiaNCT01957189 · 24 enrolled · China
  7. Jan 23, 2014Phase 3 study in Prostatic HyperplasiaNCT02058368 · 607 enrolled · China, Japan, Korea, Republic of and more
  8. Jan 30, 2014Phase 1 study in Urologic DiseasesNCT02052713 · 78 enrolled · United Kingdom
  9. Feb 6, 2014Phase 1 study in Urologic DiseasesNCT02058576 · 77 enrolled · United Kingdom

TargetBeta

“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
MidodrineruleTakedaphase 410
PrazosinrulePfizerphase 34

Studies

All 9 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02058576Urologic Diseases · United Kingdom1CompletedJan 2, 201577
NCT02052713Urologic Diseases · United Kingdom1CompletedDec 29, 201478
NCT02058368Prostatic Hyperplasia · China, Japan, Korea, Republic of and more3CompletedMar 3, 2017607
NCT01957189Prostatic Hyperplasia · China1CompletedJan 22, 201424
NCT01777269Prostatic Hyperplasia · Australia, France, Germany and more4CompletedApr 5, 2016489
NCT01657851Prostatic Hyperplasia · Russian Federation1CompletedDec 5, 201235
NCT01673490Prostatic Hyperplasia · Vietnam4TerminatedMar 20, 201559
NCT01294592Prostatic Hyperplasia · France, Germany, Greece and more4CompletedOct 17, 2013742
NCT00090103Prostatic Hyperplasia · United States, Argentina, Belgium and more3CompletedApr 20094,844

How it is read

Names in the registry

  • “Tamsulosin”, 12 entries
  • “tamsulosin hydrochloride”, 6 entries
  • “Tamsulosin (0.4 mg/j)”, 5 entries
  • “tamsulosin”, 4 entries
  • “HIP1402”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.